STAT-Diagnostica, a medical diagnostics company, had recently appointed Gerard Vallant to become the company's Chairman of the Board of Directors. His more than thirty years of experience in the medical device and diagnostics sector brings perspective and guidance to the future projects and programs of the firm.

According to CEO and co-founder of STAT-Diagnostica Jordi Carrera, "We are very privileged to have Gérard join as the chairman of our board of directors. His deep industry pedigree and proven track record of success will be invaluable to us as we move towards European and U.S. approval and commercialization of our DiagCORE platform." 

Valiant comes at a time when STAT Diagnostica had just closed a Series B financing round amounting to US$22.1 million or Eur17 million. The round was led by Kurma Life Sciences Partners together with new investors namely Idinvest, Boehringer Ingelheim Venture Fund and Caixa Capital Risc. Other existing capital investors include Ysios Capital and Axis.

The proceeds would be utlilized to complete the development of the DiagCORE platform as well as the clinical trials of its products.